Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.
The iShares Biotechnology ETF (IBB) increased 0.3%.
In corporate news, Fate Therapeutics (FATE) shares rose nearly 6% after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate to treat autoimmune diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments